Tesamorelin Co / Safety
Safety
8 articles
SafetyIs tesamorelin safe? what the FDA trials actually showTesamorelin is FDA-approved with phase 3 safety data in HIV lipodystrophy. Here's what the trials found on side effects, glucose, and who should avoid it.SafetyTesamorelin and athletes: drug testing status explainedTesamorelin is a GHRH analogue banned in competitive sport under WADA's S2 category. Here's the detection science, testing reality, and what athletes should know.SafetyTesamorelin and blood work: what to test and whenTesamorelin needs baseline and follow-up labs: IGF-1, glucose, A1c, liver enzymes. Here's what the phase 3 trials actually monitored and why it matters.SafetyTesamorelin contraindications: who should not use itEgrifta's label warns against use in active cancer, pituitary/pregnancy, and hypersensitivity to tesamorelin or mannitol. Full contraindication breakdown here.SafetyTesamorelin side effects: what the phase 3 trials actually foundFDA trials found injection site reactions in about 25% of patients and joint pain in about 13%. Here's the full side effect profile of tesamorelin, cited.SafetyTesamorelin drug interactions: what actually mattersTesamorelin has no major CYP-based drug interactions, but it can raise blood sugar and change how other drugs are dosed. Here's the real interaction list.SafetyTesamorelin long term side effects: what the trials showEgrifta's phase 3 safety extension ran 52 weeks. Here's what long term tesamorelin side effects look like in the actual trial data, and what's still unknown.SafetyTesamorelin peptide side effects: what the trials actually showInjection site reactions hit roughly 25-35% of tesamorelin users in trials. Here's the full side effect profile from the phase 3 data, plain and unranked.